

Synapse Medicine raises €7 million

Chammas & Marcheteau advises FPCI Xange Digital 3, BNP Paribas Développement and Synapse Medicine

Chammas & Marcheteau advised **Synapse Medicine** as well as cornerstone investors **FPCI Xange Digital 3** and **BNP Paribas Développement** on their investment in Synapse Medicine alongside MACSF.

Through its SaaS platform, Synapse Medicine allows doctors, pharmacists, and other healthcare professionals to easily search for reliable and up-to-date information on medicine, analyze prescriptions in real time and secure drug treatments. This investment aims to further develop Synapse Medicine's Medication Intelligence Platform, already used daily by thousands of healthcare professionals and patients. In the last 14 months, the Company has raised more than €10 million and tripled its workforce.

The **Chammas & Marcheteau** team was composed of partner **Denis Marcheteau**, counsel **Stéphanie Bréjaud** and associate **Ludivine Rabreau**.

About Synapse Medicine

Founded by two doctors and an engineer, Synapse Medicine's mission is to provide easy access to reliable and up-to-date medical information to the public. The start-up, which collaborates with some of France's largest university hospitals, has developed the first Medication Intelligence Platform dedicated to the proper use of medicine. A reference in this sector, its 100% independent solution is now used by thousands of healthcare professionals.

About Chammas & Marcheteau

Chammas & Marcheteau is a Paris-based independent law firm that advises companies, investment funds and entrepreneurs on their transactions and development strategies in France and abroad. With 35 specialists in business law, including 10 partners, the Firm offers its expertise to clients in Mergers & Acquisitions, Private Equity, Funds and Financial Services, Distressed and Turnaround, Tax, and Intellectual Property and Information Technology. The Firm has a rapidly growing international activity, including in Africa.